Key Takeaways
- • Davis, California-based ag-tech company BioConsortia Inc. raised $15 million in venture capital, led by existing investor Otter Capital, according to the Sacramento Business Journal.
- • The round funds expansion of the Davis lab and broadened global field trial programs for microbial seed treatments.
- • Publisher coverage describes the raise as a Series B and an internal round from existing investors, with the capital earmarked for commercial launch, manufacturing, and regulatory infrastructure.
- • The company's products include nitrogen-fixing microbial seed treatments and gene-edited biocontrol technologies, including the Zaffre product line.
Summary
Davis-based ag-tech company BioConsortia Inc. has raised $15 million in venture capital led by existing investor Otter Capital, according to a report by Mark Anderson of the Sacramento Business Journal dated April 2, 2024. The funding is intended to expand the company's Davis laboratory and support field trials across multiple regions.
Publisher coverage of the round describes it as closed from existing investors and, in one account, as a Series B financing. The company has been positioned as a leader in microbial innovation for sustainable agriculture. According to company announcements carried in the publisher's database, the proceeds will fund commercial launches along with the manufacturing, regulatory, and commercial infrastructure required to scale. The raise will also support broadened field trial programs in key agricultural regions globally, as well as gene-editing and nitrogen-fixing microbial development.
BioConsortia's technology centers on microbial seed treatments designed to improve crop emergence and reduce reliance on synthetic inputs. One announcement references the Zaffre product line, which the company says boosts crop emergence and stand establishment. The Sacramento Business Journal's related coverage notes that the company is moving to begin selling a product that has been under development for roughly a decade.
The round highlights continued investor interest in agricultural biotechnology as companies seek to move from research to commercial scale. Specific valuation and total investor syndicate details were not disclosed in the available coverage.
Publisher coverage of the round describes it as closed from existing investors and, in one account, as a Series B financing. The company has been positioned as a leader in microbial innovation for sustainable agriculture. According to company announcements carried in the publisher's database, the proceeds will fund commercial launches along with the manufacturing, regulatory, and commercial infrastructure required to scale. The raise will also support broadened field trial programs in key agricultural regions globally, as well as gene-editing and nitrogen-fixing microbial development.
BioConsortia's technology centers on microbial seed treatments designed to improve crop emergence and reduce reliance on synthetic inputs. One announcement references the Zaffre product line, which the company says boosts crop emergence and stand establishment. The Sacramento Business Journal's related coverage notes that the company is moving to begin selling a product that has been under development for roughly a decade.
The round highlights continued investor interest in agricultural biotechnology as companies seek to move from research to commercial scale. Specific valuation and total investor syndicate details were not disclosed in the available coverage.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.